US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company’s portfolio of product candidates targeting devastating rare diseases. Rallybio’s lead candidate is RLYB211 that the company acquired in 2019 from Prophylix Pharma. Rallybio plans to initiate a Phase 1/2 clinical study of RLY211 2H 2020

Read more